Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2025 Highlights EPKINLY® (epcoritamab) approved by the Japan Ministry of Health, Labour and Welfare (MHLW) for additional ...

Net financial items resulted in income of $56 million for the first three months of 2025 compared to $133 million in the first three months of 2024. The decrease was primarily due to a decrease in ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) yesterday approved Tepezza (teprotumumab (Tepezza). This ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for Amgen’s Tepezza ...

Amgen (AMGN) stock in focus as its antibody drug Tepezza becomes U.K.'s first medicine for adults with moderate to severe ...

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options ...

Bender Industries GmbH & Co. KG (Bender) appoints Michael Breuer as CEO and Nicole Bender as CFO. Heinz Nowicki and Dr. Sven Hartung have left the company. - Picture is available at AP - As of 1 May ...

WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, Inc.  a biotechnology company focused on the need ...

As with all products, the MHRA will keep its safety under close review. The Medicines and Healthcare products Regulatory ...

What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Wednesday showed that Busch sold 1,000 shares of Amgen. The total transaction amounted to $279,690. As of Wednesday ...

Amgen's diverse portfolio ensures stability, but risks like high debt and biosimilar competition loom. Check out my look at ...